Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid

References

• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation2002106253143342112485966
   PubMed Web of Science ®Google Scholar
• BuseJBGinsbergHNBakrisGLPrimary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes AssociationDiabetes Care200730116217217192355
   PubMed Web of Science ®Google Scholar
• SmithSCJrAllenJBlairSNAHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood InstituteCirculation2006113192363237216702489
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation2004110222723915249516
   PubMed Web of Science ®Google Scholar
• GrahamIAtarDBorch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)Eur J Cardiovasc Prev Rehabil200714 Suppl 2E1E4017726406
   PubMedGoogle Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350151495150415007110
   PubMed Web of Science ®Google Scholar
• ShepherdJBarterPCarmenaREffect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) studyDiabetes Care20062961220122616731999
   PubMed Web of Science ®Google Scholar
• DeedwaniaPBarterPCarmenaRReduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets studyLancet2006368953991992816962881
   PubMed Web of Science ®Google Scholar
• Alsheikh-AliAALinJLAbourjailyPAhearnDKuvinJTKarasRHPrevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterolAm J Cardiol2007100101499150117996508
   PubMed Web of Science ®Google Scholar
• SinghMChinSHGilesPDCrothersDAl-AllafKKhanJMControlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: Are we doing enoughEur J Cardiovasc Prev Rehabil2010318 [Epub ahead of print]
   PubMedGoogle Scholar
• SarwarNDaneshJEiriksdottirGTriglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studiesCirculation2007115445045817190864
   PubMed Web of Science ®Google Scholar
• BestJDO’NealDNDiabetic dyslipidaemia: Current treatment recommendationsDrugs20005951101111110852642
   PubMed Web of Science ®Google Scholar
• GaziITsimihodimosVFilippatosTBairaktariETselepisADElisafMConcentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteriaMetabolism200655788589116784959
   PubMed Web of Science ®Google Scholar
• LamarcheBLemieuxIDespresJPThe small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspectsDiabetes Metab199925319921110499189
   PubMed Web of Science ®Google Scholar
• AscasoJFFernandez-CruzAGonzalez SantosPSignificance of high density lipoprotein-cholesterol in cardiovascular risk prevention: Recommendations of the HDL ForumAm J Cardiovasc Drugs20044529931415449972
   PubMedGoogle Scholar
• AthyrosVGMikhailidisDPKakafikaAIIdentifying and attaining LDL-C goals: Mission accomplished? Next target: New therapeutic options to raise HDL-C levelsCurr Drug Targets20078348348817348840
   PubMed Web of Science ®Google Scholar
• Role of fibrates in reducing coronary risk: A UK ConsensusCurr Med Res Opin200420224124715006019
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• BackesJMGibsonCARuisingerJFMoriartyPMFibrates: What have we learned in the past 40 years?Pharmacotherapy200727341241417316152
   PubMed Web of Science ®Google Scholar
• Trilipix [Package insert]North Chicago, ILAbbott Laboratories2009Available from: http://www.trilipixpro.com/ Accessed on May 26, 2010
   Google Scholar
• BairaktariETTzallasCSTsimihodimosVKLiberopoulosENMiltiadousGAElisafMSComparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemiaJ Cardiovasc Risk19996211311610353071
   PubMedGoogle Scholar
• SchimaSMMaciejewskiSRHillemanDEWilliamsMAMohiuddinSMFibrate therapy in the management of dyslipidemias, alone and in combination with statins: Role of delayed-release fenofibric acidExpert Opin Pharmacother11573173820210682
   PubMed Web of Science ®Google Scholar
• AthyrosVGMikhailidisDPPapageorgiouAATargeting vascular risk in patients with metabolic syndrome but without diabetesMetabolism20055481065107416092057
   PubMed Web of Science ®Google Scholar
• StoneNJBilekSRosenbaumSRecent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and optionsAm J Cardiol2005964AE539
   PubMed Web of Science ®Google Scholar
• CaldwellJThe biochemical pharmacology of fenofibrateCardiology198976 Suppl 13341discussion 41142713875
   PubMedGoogle Scholar
• AdkinsJCFauldsDMicronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemiaDrugs19975446156339339964
   PubMed Web of Science ®Google Scholar
• ChapmanMJPharmacology of fenofibrateAm J Med1987835B21253318449
   PubMed Web of Science ®Google Scholar
• BalfourJAMcTavishDHeelRCFenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemiaDrugs19904022602902226216
   PubMed Web of Science ®Google Scholar
• TojcicJBenoit-BiancamanoMOCourtMHStrakaRJCaronPGuillemetteCIn vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomesDrug Metab Dispos200937112236224319661212
   PubMed Web of Science ®Google Scholar
• DesagerJPCostermansJVerberckmoesRHarvengtCEffect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failureNephron198231151547110477
   PubMed Web of Science ®Google Scholar
• RathNPHaqWBalendiranGKFenofibric acidActa Crystallogr C200561(Pt 2):o81o8415695917
   PubMedGoogle Scholar
• ZhuTAnsquerJCKellyMTSleepDJPradhanRSComparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humansJ Clin Pharmacol201029 [Epub ahead of print]
   Web of Science ®Google Scholar
• ZhuTAwniWMHosmaneBABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humansJ Clin Pharmacol2009491637118952910
   PubMed Web of Science ®Google Scholar
• PrueksaritanontTRichardsKMQiuYComparative effects of fibrates on drug metabolizing enzymes in human hepatocytesPharm Res200522171815771232
   PubMed Web of Science ®Google Scholar
• AhmadSGemfibrozil: Interaction with glyburideSouth Med J19918411021898783
   PubMed Web of Science ®Google Scholar
• MillerDBSpenceJDClinical pharmacokinetics of fibric acid derivatives (fibrates)Clin Pharmacokinet19983421551629515185
   PubMed Web of Science ®Google Scholar
• BergmanAJMurphyGBurkeJSimvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humansJ Clin Pharmacol20044491054106215317833
   PubMed Web of Science ®Google Scholar
• PanWJGustavsonLEAchariRLack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteersJ Clin Pharmacol200040331632310709162
   PubMed Web of Science ®Google Scholar
• GoosenTCBaumanJNDavisJAAtorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acidDrug Metab Dispos20073581315132417470524
   PubMed Web of Science ®Google Scholar
• MartinPDDaneALSchneckDWWarwickMJAn open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteersClin Ther200325245947112749507
   PubMed Web of Science ®Google Scholar
• FruchartJCDuriezPMode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolismDrugs Today (Barc)2006421396416511610
   PubMed Web of Science ®Google Scholar
• FazioSLintonMFThe role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacyCurr Atheroscler Rep20046214815715023300
   PubMedGoogle Scholar
• MinnichATianNByanLBilderGA potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscleAm J Physiol Endocrinol Metab20012802E270E27911158930
   PubMed Web of Science ®Google Scholar
• HahnSEGoldbergDMModulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrateBiochem Pharmacol19924336256331311585
   PubMed Web of Science ®Google Scholar
• DesagerJPHorsmansYVandenplasCHarvengtCPharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 daysAtherosclerosis1996124 SupplS65S738831918
   PubMedGoogle Scholar
• StaelsBVu-DacNKosykhVAFibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibratesJ Clin Invest19959527057127860752
   PubMed Web of Science ®Google Scholar
• SasakiJYamamotoKAgetaMEffects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: A randomized, double-blind, placebo-controlled, multicenter, crossover studyClin Ther200224101614162612462290
   PubMed Web of Science ®Google Scholar
• AnderssonYMajdZLefebvreAMDevelopmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulationArterioscler Thromb Vasc Biol19991911151219888873
   PubMed Web of Science ®Google Scholar
• LemieuxISalomonHDespresJPContribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patientsAnn Med200335644244814572169
   PubMed Web of Science ®Google Scholar
• FilippatosTDKiortsisDNLiberopoulosENGeorgoulaMMikhailidisDPElisafMSEffect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: The FenOrli studyCurr Med Res Opin200521121997200616368051
   PubMed Web of Science ®Google Scholar
• BerthouLSaladinRYaqoobPRegulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acidsEur J Biochem199523211791877556148
   PubMedGoogle Scholar
• FilippatosTDLiberopoulosENKostapanosMThe effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndromeDiabetes Obes Metab200810647648317459096
   PubMed Web of Science ®Google Scholar
• GuerinMBruckertEDolphinPJTurpinGChapmanMJFenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemiaArterioscler Thromb Vasc Biol19961667637728640404
   PubMed Web of Science ®Google Scholar
• WattsGFJiJChanDCRelationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndromeClin Sci (Lond)2006111319319916700661
   PubMed Web of Science ®Google Scholar
• ArakawaRTamehiroNNishimaki-MogamiTUedaKYokoyamaSFenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent mannerArterioscler Thromb Vasc Biol20052561193119715790930
   PubMed Web of Science ®Google Scholar
• ChinettiGLestavelSBocherVPPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathwayNat Med200171535811135616
   PubMed Web of Science ®Google Scholar
• MageeGSharpePCParadoxical decreases in high-density lipoprotein cholesterol with fenofibrate: A quite common phenomenonJ Clin Pathol200962325025319251953
   PubMed Web of Science ®Google Scholar
• MombelliGPazzucconiFBondioliAParadoxical decrease in high-density lipoprotein cholesterol with fenofibrate: A quite rare phenomenon indeedCardiovasc Ther2010310 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• SchneiderAStangeEFDitschuneitHHDitschuneitHFenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patientsAtherosclerosis19855632572624052147
   PubMed Web of Science ®Google Scholar
• BrownWVFocus on fenofibrateHosp Pract (Off Ed)198823 Suppl 131403134383
   PubMedGoogle Scholar
• ElisafMEffects of fibrates on serum metabolic parametersCurr Med Res Opin200218526927612240789
   PubMed Web of Science ®Google Scholar
• FilippatosTMilionisHJTreatment of hyperlipidaemia with fenofibrate and related fibratesExpert Opin Investig Drugs2008171015991614
   PubMed Web of Science ®Google Scholar
• LeeJJJinYRYuJYAntithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drugAtherosclerosis2009206237538219345949
   PubMed Web of Science ®Google Scholar
• HamiltonSJChewGTDavisTMWattsGFFenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated type 2 diabetic patientsClin Sci (Lond)20101181060761520047560
   PubMed Web of Science ®Google Scholar
• KohKKHanSHQuonMJYeal AhnJShinEKBeneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemiaDiabetes Care20052861419142415920062
   PubMed Web of Science ®Google Scholar
• SaougosVGTambakiAPKalogirouMDifferential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2Arterioscler Thromb Vasc Biol200727102236224317656665
   PubMed Web of Science ®Google Scholar
• LiamisGBairaktariETElisafMSEffect of fenofibrate on serum uric acid levelsAm J Kidney Dis199934359410469875
   PubMed Web of Science ®Google Scholar
• BelfortRBerriaRCornellJCusiKFenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndromeJ Clin Endocrinol Metab201095282983620061429
   PubMed Web of Science ®Google Scholar
• BirjmohunRSHuttenBAKasteleinJJStroesESEfficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trialsJ Am Coll Cardiol200545218519715653014
   PubMed Web of Science ®Google Scholar
• KnoppRHBrownWVDujovneCAEffects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemiaAm J Med1987835B50593318454
   PubMed Web of Science ®Google Scholar
• KornitzerMDramaixMVandenbroekMDEveraertLGerlingerCEfficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: An open Belgian multicenter studyAtherosclerosis1994110 SupplS49S547857385
   PubMedGoogle Scholar
• BrownWVPotential use of fenofibrate and other fibric acid derivatives in the clinicAm J Med1987835B85893688012
   PubMed Web of Science ®Google Scholar
• FranceschiniGCalabresiLColomboCFavariEBerniniFSirtoriCREffects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patientsAtherosclerosis2007195238539117109866
   PubMed Web of Science ®Google Scholar
• MayHTAndersonJLPearsonRRComparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study)Am J Cardiol2008101448648918312763
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLYuanZBattistiWPBradyWEPalmisanoJEffectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)Am J Cardiol200595446246815695129
   PubMed Web of Science ®Google Scholar
• KontushAChantepieSChapmanMJSmall, dense HDL particles exert potent protection of atherogenic LDL against oxidative stressArterioscler Thromb Vasc Biol200323101881188812920049
   PubMed Web of Science ®Google Scholar
• de SouzaJAVindisCNegre-SalvayreASmall, dense HDL3 particles attenuates apoptosis in endothelial cells: Pivotal role of apolipoprotein A-IJ Cell Mol Med201014360862019243471
   PubMed Web of Science ®Google Scholar
• RuotoloGEricssonCGTettamantiCTreatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)J Am Coll Cardiol1998326164816569822092
   PubMed Web of Science ®Google Scholar
• OtvosJDCollinsDFreedmanDSLow-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention TrialCirculation2006113121556156316534013
   PubMed Web of Science ®Google Scholar
• FrickMHEloOHaapaKHelsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart diseaseN Engl J Med198731720123712453313041
   PubMed Web of Science ®Google Scholar
• FrickMHSyvanneMNieminenMSPrevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study GroupCirculation1997967213721439337181
   PubMed Web of Science ®Google Scholar
• de FaireUEricssonCGGripLNilssonJSvaneBHamstenASecondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)Eur Heart J199617 Suppl F37428960446
   PubMedGoogle Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupN Engl J Med1999341641041810438259
   PubMed Web of Science ®Google Scholar
• Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) studyCirculation20001021212710880410
   PubMed Web of Science ®Google Scholar
• KeechASimesRJBarterPEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trialLancet200536695001849186116310551
   PubMed Web of Science ®Google Scholar
• ScottRO’BrienRFulcherGEffects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyDiabetes Care200932349349818984774
   PubMed Web of Science ®Google Scholar
• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised studyLancet2001357926090591011289345
   PubMed Web of Science ®Google Scholar
• BruckertEDe GennesJLMalbecqWBaigtsFComparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemiaClin Cardiol199518116216298590530
   PubMed Web of Science ®Google Scholar
• EllenRLMcPhersonRLong-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemiaAm J Cardiol1998814AB60B65
   PubMed Web of Science ®Google Scholar
• AthyrosVGPapageorgiouAAAthyrouVVDemitriadisDSKontopoulosAGAtorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemiaDiabetes Care20022571198120212087019
   PubMed Web of Science ®Google Scholar
• KiortisisDNMillionisHBairaktariEElisafMSEfficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemiaEur J Clin Pharmacol2000569–1063163511214768
   PubMed Web of Science ®Google Scholar
• LiamisGKakafikaABairaktariECombined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemiaCurr Med Res Opin200218312512812094821
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAEBertoneGPiccinniMNCiccarelliLRoggeriDEComparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: A 12-month, randomized, double-blind, controlled trialClin Ther200426101599160715598476
   PubMed Web of Science ®Google Scholar
• VegaGLMaPTCaterNBEffects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndromeAm J Cardiol200391895696012686335
   PubMed Web of Science ®Google Scholar
• GinsbergHNElamMBLovatoLCEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med2010362171563157420228404
   PubMed Web of Science ®Google Scholar
• JonesPHBaysHEDavidsonMHEvaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : Study design and rationale of a Phase III clinical programmeClin Drug Investig20082810625634
   PubMed Web of Science ®Google Scholar
• MohiuddinSMPepineCJKellyMTEfficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled studyAm Heart J2009157119520319081418
   PubMed Web of Science ®Google Scholar
• GoldbergACBaysHEBallantyneCMEfficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemiaAm J Cardiol200910345152219195513
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHKashyapMLEfficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 studyAtherosclerosis2009204120821518996523
   PubMed Web of Science ®Google Scholar
• KipnesMSRothEMRhyneJMYear two assessment of fenofibric acid and moderate-dose statin combination: A phase 3, open-label, extension studyClin Drug Investig20103015161
   PubMed Web of Science ®Google Scholar
• JonesPHCusiKDavidsonMHEfficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: Results of a pooled subgroup analysis from three randomized, controlled, double-blind trialsAm J Cardiovasc Drugs2010102738420136164
   PubMed Web of Science ®Google Scholar
• BroedersNKnoopCAntoineMTielemansCAbramowiczDFibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent?Nephrol Dial Transplant200015121993199911096145
   PubMed Web of Science ®Google Scholar
• AnsquerJCDaltonRNCausseECrimetDLe MalicotKFoucherCEffect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy peopleAm J Kidney Dis200851690491318501783
   PubMed Web of Science ®Google Scholar
• TsimihodimosVKakafikaAElisafMFibrate treatment can increase serum creatinine levelsNephrol Dial Transplant2001166130111390746
   PubMed Web of Science ®Google Scholar
• TsimihodimosVMiltiadousGBairaktariEElisafMPossible mechanisms of the fibrate-induced increase in serum creatinineClin Nephrol200257540740812036205
   PubMed Web of Science ®Google Scholar
• ForsblomCHiukkaALeinonenESSundvallJGroopPHTaskinenMREffects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: The FIELD Helsinki substudyDiabetes Care201033221522019846798
   PubMed Web of Science ®Google Scholar
• MelenovskyVMalikJWichterleDComparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemiaAm Heart J20021444E612360175
   PubMedGoogle Scholar
• DierkesJWestphalSLuleyCFenofibrate-induced hyperhomocysteinaemia: Clinical implications and managementDrug Saf2003262819112534325
   PubMed Web of Science ®Google Scholar
• MilionisHJPapakostasJKakafikaAChasiotisGSeferiadisKElisafMSComparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemiaJ Clin Pharmacol200343882583012953339
   PubMed Web of Science ®Google Scholar
• MikaelLGGenestJJrRozenRElevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery diseaseCirc Res200698456457116439690
   PubMed Web of Science ®Google Scholar
• KostapanosMSMilionisHJElisafMSRosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemiaAm J Cardiovasc Drugs20101112820104931
   PubMedGoogle Scholar
• RosensonRSCurrent overview of statin-induced myopathyAm J Med2004116640841615006590
   PubMed Web of Science ®Google Scholar
• Alsheikh-AliAAKuvinJTKarasRHRisk of adverse events with fibratesAm J Cardiol200494793593815464682
   PubMed Web of Science ®Google Scholar
• CorsiniABellostaSDavidsonMHPharmacokinetic interactions between statins and fibratesAm J Cardiol2005969AK44K49discussion K345
   PubMed Web of Science ®Google Scholar
• JonesPHDavidsonMHReporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statinAm J Cardiol200595112012215619408
   PubMed Web of Science ®Google Scholar
• UnalATorunESipahiogluMHFenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patientsIntern Med200847111017101918520113
   PubMed Web of Science ®Google Scholar
• IrelandJHEggertCHArendtCJWilliamsAWRhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrateAnn Intern Med20051421194995015941707
   PubMed Web of Science ®Google Scholar
• KursatSAliciTColakHBA case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidismClin Nephrol200564539139316312269
   PubMed Web of Science ®Google Scholar
• SatarasingheRLRameshRRiyaazAAGunarathnePAde SilvaAPHypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis – patient report and literature reviewDrug Metabol Drug Interact200722427928318447003
   PubMedGoogle Scholar
• Standards of medical care in diabetes – 2008Diabetes Care200831 Suppl 1S12S5418165335
   PubMedGoogle Scholar
• LiberopoulosENFlorentinMMikhailidisDPElisafMSCompliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortalityExpert Opin Drug Saf20087671772518983218
   PubMed Web of Science ®Google Scholar